Prelude Therapeutics
PRLD
53 hedge funds and large institutions have $144M invested in Prelude Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 13 closing their positions.
22% more capital invested
Capital invested by funds: $119M → $144M (+$25.5M)
18.72% more ownership
Funds ownership: 68.63% → 87.35% (+19%)
15% less funds holding
Funds holding: 62 → 53 (-9)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.26M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$847K |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$234K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$229K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.04M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.93M |
| 3 |
Two Sigma Advisers
New York
|
-$851K |
| 4 |
Two Sigma Investments
New York
|
-$797K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$633K |
PRLD Hedge Fund Activity: Q3 2022 in Review
53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2022, worth a combined $144M — up 22% from $119M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PRLD and 5 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was Fidelity Investments, adding an estimated $2.26M. The largest seller was Morgan Stanley, cutting an estimated $2.04M.
- 53 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2022, down from 62 in Q2 2022.
- Funds reported $144M of Prelude Therapeutics stock for Q3 2022, up 22% quarter-over-quarter.
- 5 funds opened new Prelude Therapeutics positions in Q3 2022 and 13 closed out, a net change of -8 holders.
- The largest Prelude Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $2.26M added.
- The largest Prelude Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $2.04M sold.
Based on aggregated 13F filings for Q3 2022.